FCM
AUPH icon

Farallon Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Farallon Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,000,000
Closed -$14.7M – 139
2020
Q3 		$14.7M Buy
+1,000,000
New +$14.5M 0.1% 93

Other funds holding AUPH

HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Farallon Capital Management's AUPH Position: Q4 2020 in Review

Farallon Capital Management sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2020, closing a stake of 1,000,000 shares — an estimated $14.7M sold.

Farallon Capital Management first reported a position in AUPH in Q3 2020 and held it in 1 quarter. The position peaked at $14.7M in Q3 2020. 145 funds tracked by Wall St. Rank hold AUPH as of Q4 2020.

  • Farallon Capital Management reported no remaining Aurinia Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Farallon Capital Management sold 1,000,000 Aurinia Pharmaceuticals shares in Q4 2020, an estimated $14.7M.
  • Farallon Capital Management first reported a position in Aurinia Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Farallon Capital Management's Aurinia Pharmaceuticals position peaked at $14.7M in Q3 2020.
  • 145 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2020.

Based on Farallon Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.